PARK7 (Parkinson Disease (Autosomal Recessive, Early Onset) 7, DJ-1, DJ1, FLJ27376, FLJ34360, FLJ92274)

Antibodies / Antibodies-Oncoproteins

-20°C

Supplied as a liquid in PBS, pH 7.3, 0.02% sodium azide, 50% glycerol.

Recombinant protein corresponding to human PARK7.

Parkinson's disease (PD) is characterized by the presence of Lewy bodies (intracellular inclusions) and by the loss of dopaminergic neurons. Research studies have shown that mutations in alpha-synuclein, Parkin, and DJ-1 are linked to PD (1). alpha-synuclein is a major component of the aggregates found in Lewy bodies. Parkin is involved in protein degradation through the ubiquitin-proteasome pathway, and investigators have shown that mutations in Parkin cause early onset of PD (1). Loss-of-function mutations in DJ-1 cause early onset of PD, but DJ-1 is associated with multiple functions: it cooperates with Ras to increase cell transformation, it positively regulates transcription of the androgen receptor, and it may function as an indicator of oxidative stress (2-5). Dopamine D2 receptor-mediated functions are greatly impaired in DJ-1 (-/-) mice, resulting in reduced long-term depression (6).

Applications:
Suitable for use in Immunofluorescence, Western Blot, Immunoprecipitation, Immunohistochemistry, Immunocytochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:500-1:2000
Immunohistochemistry: 1:50-1:200
Immunocytochemistry: 1:20-1:100
Immunofluorescence: 1:50-1:200
Immunoprecipitation: 1:20-1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.